Types segmentation classifies adjuvant therapy by therapeutic modality, each with distinct mechanistic and economic profiles. Conventional chemotherapy remains the largest type, representing roughly 45 % of market value, as agents such as cyclophosphamide, 5‑fluorouracil, and paclitaxel are incorporated into multi‑agent regimens across multiple cancers. Targeted therapy, defined by agents that inhibit specific oncogenic pathways (e.g., HER2 inhibitors, BRAF inhibitors), accounts for approximately 30 % of the market; its growth is driven by biomarker‑guided approvals that expand the eligible patient pool. Immunotherapy, primarily checkpoint inhibitors used after surgical resection, contributes about 15 % and is rapidly scaling due to durable response data in melanoma and lung cancer. Hormonal therapy, limited to hormone‑responsive tumors such as breast and prostate, holds a 7 % share, reflecting long‑standing guideline endorsement and generic competition. The remaining 3 % comprises emerging modalities, including antibody‑drug conjugates and cellular therapies, which are currently niche but poised for future expansion. This adjuvant therapy segmentation underscores how therapeutic diversification influences R&D allocation and pricing structures within the market taxonomy.
